If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

10 Oct 2022 08:03

RNS Number : 3180C
e-Therapeutics plc
10 October 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B2823H99

Issuer Name

E-THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

Other

Comments

This is due to a placing of subscription shares.

3. Details of person subject to the notification obligation

Name

M&G Plc

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

06-Oct-2022

6. Date on which Issuer notified

07-Oct-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

17.500840

0.000000

17.500840

101875000

Position of previous notification (if applicable)

9.813161

0.000000

9.813161

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00B2823H99

101875000

17.500840

Sub Total 8.A

101875000

17.500840%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

M&G Plc

M&G Plc (Parent Company)

17.500840

17.500840%

M&G Plc

M&G Group Regulated Entity Holding Company Limited (wholly owned subsidiary of M&G Plc)

17.500840

17.500840%

M&G Plc

M&G Group Limited (wholly owned subsidiary of M&G Group Regulated Entity Holding Company Limited)

17.500840

17.500840%

M&G Plc

M&G FA Limited (wholly owned subsidiary of M&G Group Limited)

17.500840

17.500840%

M&G Plc

M&G Investment Management Limited (wholly owned subsidiary of M&G FA Limited)

17.500840

17.500840%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-Oct-2022

13. Place Of Completion

London, United Kingdom

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAXEEFEAAFEA
Date   Source Headline
12th Apr 20227:00 amRNSKey Milestone Achieved on Galapagos Collaboration
5th Apr 20227:00 amRNSImmuno-Oncology Research Collaboration with iTeos
16th Feb 20224:41 pmRNSHolding(s) in Company
16th Feb 202211:47 amRNSHolding(s) in Company
15th Feb 20223:27 pmRNSHolding(s) in Company
31st Jan 20227:00 amRNSTotal Voting Rights
20th Jan 202210:58 amRNSNew Corporate Website
18th Jan 20224:41 pmRNSHolding(s) in Company
7th Jan 20227:00 amRNSDirector Dealing and Issue of Equity
22nd Nov 20217:00 amRNSSenior Management Update
26th Oct 20211:55 pmRNSDirector Dealing
26th Oct 20217:01 amRNSInterim results for six months ended 31 July 2021
26th Oct 20217:00 amRNSRNAi Platform Characterisation Results
20th Oct 20217:00 amRNSInvestor Presentation
11th Oct 20217:05 amRNSPatent Filing Applications
11th Oct 20217:00 amRNSNotice of Interim Results
24th Sep 20217:00 amRNSCommencement of trading on the OTCQX Best Market
2nd Sep 20214:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20214:35 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSTotal Voting Rights
6th Jul 20217:00 amRNSDirector Dealing and Issue of Equity
2nd Jul 20217:00 amRNSFurther milestone in Galapagos collaboration
30th Jun 20217:00 amRNSTotal Voting Rights
21st Jun 20213:13 pmRNSHolding(s) in Company
21st Jun 20217:00 amRNSHolding(s) in Company
18th Jun 202112:52 pmRNSHolding(s) in Company
17th Jun 20213:44 pmRNSHolding(s) in Company
16th Jun 20211:27 pmRNSResult of AGM
2nd Jun 20217:00 amRNSSenior Management Appointment and Options Grant
21st May 20217:00 amRNSNotice of AGM and Posting of Annual Report
14th May 20217:00 amRNSResults of conditional Fundraise to raise £22.5m
13th May 20214:50 pmRNSRetail Offer
13th May 20214:45 pmRNSProposed Fundraise in excess of £20 million
13th May 20217:00 amRNSFinal Results for the Year Ended 31 January 2021
6th May 20217:00 amRNSNotification of Full Year Results Date
23rd Apr 20217:00 amRNSETX to receive two payments from Galapagos
29th Mar 20217:00 amRNSAppointment of Chief Financial Officer
1st Mar 20217:00 amRNSChange of Adviser
1st Mar 20217:00 amRNSBoard Changes
25th Feb 20213:29 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSe-therapeutics to present at Shares Evening
10th Feb 20214:35 pmRNSHolding(s) in Company
1st Feb 20217:00 amRNSRNA Therapeutics Platform
28th Jan 20214:40 pmRNSSecond Price Monitoring Extn
28th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:36 pmRNSPrice Monitoring Extension
12th Jan 202111:24 amRNSHolding(s) in Company
4th Jan 20214:31 pmRNSDirector/PDMR Shareholding
18th Dec 20205:44 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.